NO20021500L - Farmasöytiske preparater av fibrinolytisk middel - Google Patents

Farmasöytiske preparater av fibrinolytisk middel

Info

Publication number
NO20021500L
NO20021500L NO20021500A NO20021500A NO20021500L NO 20021500 L NO20021500 L NO 20021500L NO 20021500 A NO20021500 A NO 20021500A NO 20021500 A NO20021500 A NO 20021500A NO 20021500 L NO20021500 L NO 20021500L
Authority
NO
Norway
Prior art keywords
fibrinolytic agent
pharmaceutical preparations
lyophilized
agent
lyophilized composition
Prior art date
Application number
NO20021500A
Other languages
English (en)
Other versions
NO20021500D0 (no
Inventor
Brent S Kendrick
Brian Peterson
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20021500D0 publication Critical patent/NO20021500D0/no
Publication of NO20021500L publication Critical patent/NO20021500L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20021500A 1999-10-01 2002-03-26 Farmasöytiske preparater av fibrinolytisk middel NO20021500L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/411,335 US6440414B1 (en) 1999-10-01 1999-10-01 Pharmaceutical compositions of fibrinolytic agent
PCT/US2000/027022 WO2001024817A2 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent

Publications (2)

Publication Number Publication Date
NO20021500D0 NO20021500D0 (no) 2002-03-26
NO20021500L true NO20021500L (no) 2002-05-27

Family

ID=23628514

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021500A NO20021500L (no) 1999-10-01 2002-03-26 Farmasöytiske preparater av fibrinolytisk middel

Country Status (28)

Country Link
US (4) US6440414B1 (no)
EP (2) EP1438967A3 (no)
JP (1) JP2003510369A (no)
KR (1) KR100717435B1 (no)
CN (2) CN101209347A (no)
AT (1) ATE262923T1 (no)
AU (1) AU769313B2 (no)
BG (1) BG106578A (no)
BR (1) BR0014420A (no)
CA (1) CA2385966A1 (no)
CZ (1) CZ20021033A3 (no)
DE (2) DE60009529T2 (no)
DK (1) DK1220685T3 (no)
EA (2) EA004627B1 (no)
ES (2) ES2224917T1 (no)
HK (1) HK1049112B (no)
HU (1) HUP0202654A3 (no)
IL (1) IL148842A0 (no)
MX (1) MXPA02003197A (no)
NO (1) NO20021500L (no)
NZ (4) NZ540967A (no)
PL (1) PL355016A1 (no)
PT (1) PT1220685E (no)
SG (1) SG148823A1 (no)
SK (1) SK4242002A3 (no)
WO (1) WO2001024817A2 (no)
YU (1) YU23302A (no)
ZA (1) ZA200202400B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US7033776B2 (en) 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US20050239746A1 (en) * 2002-02-01 2005-10-27 Penkler Lawrence J Pharmaceutical composition
WO2003068805A2 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
JP5201992B2 (ja) * 2004-12-15 2013-06-05 バイオビトラム・アクテイエボラーグ（パブリツク） ケラチノサイト増殖因子の治療用製剤
KR20080076907A (ko) * 2005-11-18 2008-08-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 유도체의 제조 방법
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
KR100807692B1 (ko) * 2006-11-08 2008-02-28 신라대학교 산학협력단 혈전용해성 메탈로프로테아제 및 이를 포함하는 조성물
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
CA2742328C (en) 2008-11-07 2019-02-26 Baxter International Inc. Factor viii formulations
KR20120050442A (ko) * 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
CN102000022A (zh) * 2010-11-23 2011-04-06 郑州大学 注射用重组双功能纤溶酶冻干制剂及其制备方法
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
US20140212405A1 (en) 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
US11137409B2 (en) * 2014-11-06 2021-10-05 The Regents Of The University Of Colorado, A Body Corporate Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
CN113382714A (zh) * 2019-01-06 2021-09-10 恩多全球美学有限公司 胶原酶制剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
JPS57500844A (no) * 1980-06-27 1982-05-13
US4447236A (en) * 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) * 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) * 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) * 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) * 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US4848700A (en) * 1987-04-16 1989-07-18 Lockheed John A Canard control system for aircraft
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) * 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
ES2180528T3 (es) 1990-01-16 2003-02-16 Ct Ingenieria Genetica Biotech Metodo de expresion de genes heterologos en la levadura pichia pastoris, vectores de expresion y microorganismos transformados.
US5709676A (en) * 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) * 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) * 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) * 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
AU692497B2 (en) 1993-12-17 1998-06-11 Asahi Kasei Pharma Corporation Soluble thrombomodulin-containing pharmaceutical composition
US5626564A (en) * 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
WO1997045105A1 (en) 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US5951981A (en) 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US20020081685A1 (en) 2000-08-03 2002-06-27 Fox Brian A. Disintegrin homologs, ZSNK10, ZSNK11, and ZSNK12

Also Published As

Publication number Publication date
HUP0202654A3 (en) 2003-11-28
EP1220685A2 (en) 2002-07-10
EP1220685B1 (en) 2004-03-31
EP1438967A3 (en) 2005-01-26
ES2224917T1 (es) 2005-03-16
NZ518007A (en) 2004-03-26
JP2003510369A (ja) 2003-03-18
EA004627B1 (ru) 2004-06-24
CA2385966A1 (en) 2001-04-12
US20060246053A1 (en) 2006-11-02
CZ20021033A3 (cs) 2003-06-18
US6440414B1 (en) 2002-08-27
KR20020053065A (ko) 2002-07-04
HUP0202654A2 (hu) 2002-12-28
EA006600B1 (ru) 2006-02-24
AU769313B2 (en) 2004-01-22
HK1049112A1 (en) 2003-05-02
EA200400182A1 (ru) 2004-08-26
BG106578A (bg) 2003-04-30
CN100353999C (zh) 2007-12-12
HK1049112B (zh) 2005-01-21
ATE262923T1 (de) 2004-04-15
DE04007657T1 (de) 2005-01-13
AU7743000A (en) 2001-05-10
CN1402641A (zh) 2003-03-12
BR0014420A (pt) 2002-06-11
IL148842A0 (en) 2002-09-12
NO20021500D0 (no) 2002-03-26
US7244426B2 (en) 2007-07-17
NZ540967A (en) 2007-02-23
DE60009529D1 (de) 2004-05-06
SG148823A1 (en) 2009-01-29
US7138114B2 (en) 2006-11-21
ZA200202400B (en) 2003-05-28
DK1220685T3 (da) 2004-08-02
US7311908B2 (en) 2007-12-25
NZ530959A (en) 2005-08-26
US20020192207A1 (en) 2002-12-19
WO2001024817A2 (en) 2001-04-12
YU23302A (sh) 2005-06-10
EA200200396A1 (ru) 2002-10-31
US20060263347A1 (en) 2006-11-23
MXPA02003197A (es) 2002-09-30
EP1438967A2 (en) 2004-07-21
NZ550200A (en) 2008-04-30
DE60009529T2 (de) 2005-04-14
PT1220685E (pt) 2004-08-31
CN101209347A (zh) 2008-07-02
SK4242002A3 (en) 2003-08-05
WO2001024817A3 (en) 2001-10-18
PL355016A1 (en) 2004-03-22
ES2218228T3 (es) 2004-11-16
KR100717435B1 (ko) 2007-05-14

Similar Documents

Publication Publication Date Title
NO20021500D0 (no) Farmasöytiske preparater av fibrinolytisk middel
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
PT762896E (pt) Composicoes de tocoferol para administracao de agentes biologicamente activos
MY133996A (en) Compounds for the treatment of ischemia
CA2376193A1 (en) Therapeutic agent comprising a botulinum neurotoxin
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
PT1083884E (pt) Processo para a estabilizacao de composicoes de polivinil-pirrolidona
BR9810495A (pt) Composição farmacêutica
NO944764D0 (no) Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåter
DE69331739T2 (de) Neuartige pharmazeutische verwendungen von krill-enzymen
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
PT1054686E (pt) Formulacao farmaceutica de um composto de didemnina
PT1173194E (pt) Sp-a recombinante para o tratamento ou a prevencao da infeccao e da inflamacao pulmonares
MX9100974A (es) Enzima fibrinolitica hibrida y procedimiento para su preparacion.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application